Tag: Immunotherapy

84.9 percent of 73 patients achieved objective response, including 23.3 percent with complete response

Sequential approach is feasible and safe for peanut allergy, with very low frequency of rescue epinephrine use

Quality of life favored the pembrolizumab arm versus standard-of-care arm receiving ipilimumab, high-dose interferon α 2b

Overall incidence of treatment-related adverse events was 91.2 percent and included lymphopenia, nausea, neutropenia

Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition

Trial did not meet primary efficacy end point of disease-free survival in patients with localized RCC at high risk for postnephrectomy relapse

In Phase I/II trial of durvalumab with neoadjuvant chemo, pathological complete response rates similar for Black, non-Black patients

Patients receiving nivolumab had an approximately 30 percent lower likelihood of developing cancer recurrence versus placebo

Progression-free and overall survival similar for minority, nonminority patients receiving CAR-T cell therapy for non-Hodgkin lymphoma

Receipt of immunotherapy compared with no cancer treatment in the four weeks preceding COVID-19 diagnosis associated with lower mortality